We've all seen impressive demos of prototype brain implants being used by paralyzed patients to interface with computers, but none of those implants have entered general clinical use. Biomedical device company Synchron is close to actually coming to market with its stentrode technology, promising less spectacular results than some of its competitors, but making up for that with ease of use and implant longevity. Synchron's co-founder Tom Oxley talks with IEEE Spectrum senior editor Eliza Strickland about the new tech, and you can read more in our January issue article by Emily Waltz.